HONG KONG, Nov. 14, 2025 /PRNewswire/ — PhotonPay, an AI-powered financial infrastructure provider, has officially joined Circle’s Arc public testnet, an open, developer-friendly Layer-1 blockchain network designed to bring real-world economic activity onchain and evolve into the next-generation Economic Operating System (OS) for the internet.
Working alongside leading innovators in global payments, technology, and fintech, this initiative represents a major stride toward building open, programmable financial infrastructure. It also highlights a key shift in modernizing global payment systems and empowering enterprises to adopt blockchain-driven financial solutions.
Trusted by 200,000+ businesses worldwide to overcome banking and payment challenges, PhotonPay delivers simple, scalable, and customizable solutions – including accounts, card issuing, global payouts, online payment, FX management, and embedded finance.
Arc marks a significant milestone in developing open financial networks for the global economy. With predictable dollar-based fees, sub-second transaction finality, optional privacy configurations, and seamless integration into Circle’s full-stack platform, Arc supports diverse use cases across lending, capital markets, FX, and international payments.
Through its participation in Arc’s testnet, PhotonPay seeks to bridge traditional finance with blockchain-powered innovation, advancing transparency, security, and efficiency across the global financial ecosystem.
View original content:https://www.prnewswire.co.uk/news-releases/photonpay-joins-circles-arc-public-testnet-to-advance-global-payment-innovation-302615689.html
•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…
June 05, 2026 19:30 ET | Source: Oban BioPharma, Inc. STAMFORD, Conn., June 05, 2026…
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…
June 05, 2026 20:13 ET | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and…